SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (988)5/15/1998 9:54:00 AM
From: Russian Bear  Respond to of 1826
 
David,

Agreed. MOGN is still (or, perhaps, "again" is more appropriate) priced attractively. That said, I wouldn't mind getting another opportunity to sell in the twenties. ;-) If that opportunity does not come soon, I can wait.

And, if any of the upcoming Phase II studies show what the pre-clinicals did (_very_ big "if,") $20 per share will be an order of magnitude too cheap!

Regards,
RB



To: David Cathcart who wrote (988)5/15/1998 9:54:00 AM
From: Russian Bear  Respond to of 1826
 
Sorry, this was a duplicate of the last message. I deleted it.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News